title: Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms.
abstract: Although the central nervous system (CNS) is often regarded as an immunologically privileged site, it is well established that specific CNS immunoreactivity can be generated through peripheral vaccination with CNS antigens. Dendritic cells (DC) are potent antigen presenting cells of hematopoietic origin that have emerged as a promising tool for cancer immunotherapy capable of evoking significant anti-tumor immunity when pulsed with tumor-associated peptides. To explore a role for DC-based immunization strategies for the treatment of CNS tumors, we developed a brain tumor model using the C3 sarcoma cell line which expresses the tumor-specific, major histocompatibility complex (MHC) class I-restricted peptide epitope E7(49-57). Syngeneic C57Bl/6 mice receiving intravenous (i.v.) injections of bone marrow-derived DCs pulsed with E7 peptide were effectively protected against a subsequent intracerebral challenge with C3 tumor cells. More importantly, this systemic immunization strategy was effective in a therapy model as 67% of animals (10 of 15) with established (day 7) intracerebral C3 tumors treated with 3 weekly injections of E7 peptide-pulsed DCs achieved a long-term survival (>90 days) while no control animals survived beyond day 41. In vivo depletion of CD8+ cells, but not CD4+ or asialo-GM1+ cells, abrogated the efficacy of E7 peptide-pulsed DC therapy of established tumors, indicating a pivotal role of specific CD8+ T-cell responses in mediating the anti-tumor effect. Our findings support the hypothesis that effective CNS anti-tumor immunoreactivity can be generated with DC-based tumor vaccines.
authors.affiliation: Department of Neurosurgery, University of Pittsburgh School of Medicine, PA, USA.
authors.forename: H
authors.initials: H
authors.lastname: Okada
authors.forename: H
authors.initials: H
authors.lastname: Tahara
authors.forename: M R
authors.initials: MR
authors.lastname: Shurin
authors.forename: J
authors.initials: J
authors.lastname: Attanucci
authors.forename: K M
authors.initials: KM
authors.lastname: Giezeman-Smits
authors.forename: W K
authors.initials: WK
authors.lastname: Fellows
authors.forename: M T
authors.initials: MT
authors.lastname: Lotze
authors.forename: W H
authors.initials: WH
authors.lastname: Chambers
authors.forename: M E
authors.initials: ME
authors.lastname: Bozik
mesh_terms: D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology / Q000627:therapeutic use*; D001854:Bone Marrow Cells / Q000166:cytology / Q000276:immunology*; D001932:Brain Neoplasms / Q000276:immunology / Q000517:prevention & control*; D018414:CD8-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D003713:Dendritic Cells / Q000187:drug effects / Q000276:immunology*; D000939:Epitopes / Q000627:therapeutic use; D015395:Histocompatibility Antigens Class I / Q000276:immunology / Q000627:therapeutic use; D016219:Immunotherapy, Adoptive / Q000379:methods*; D016131:Lymphocyte Subsets / Q000187:drug effects / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D009842:Oligopeptides / Q000276:immunology / Q000627:therapeutic use
chemical_list: D000951:Antigens, Neoplasm; D000939:Epitopes; D015395:Histocompatibility Antigens Class I; D009842:Oligopeptides